Cough serves a protective physiologic function as a vital defensive reflex preventing aspiration. However, exposure to viral infections or other triggers induces, in some individuals, a chronic cough ...

As friends and family gather this holiday season, there’s a warning for new parents. The CDC says cases of pertussis, or whooping cough, remain elevated this year. An unvaccinated infant died from the ...

MILAN -- Twice-daily doses of the oral P2X3 receptor antagonist gefapixant may improve refractory or unexplained chronic cough, but at the cost of adverse events, a meta-analysis and systematic review ...

COLUMBUS, Ohio (WCMH) — Holiday cheer is in the air, and so are infections. According to the Centers for Disease Control and Prevention, whooping cough cases in the United States are beginning to ...

On Monday, Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of patients with refractory chronic cough ...

Haduvio met the primary endpoint with a statistically-significant reduction (p<0.0001) in 24-hour cough frequency with a 57% placebo-adjusted change from baseline Haduvio showed similar efficacy in ...

Shares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER ...

Please provide your email address to receive an email when new articles are posted on . There is a disconnect between cough scientists and the FDA in what represents a meaningful outcome for chronic ...

Executives from Merck, Bellus Health, Bayer, and Shionogi highlighted their P2X3 data for chronic cough. Four pharmaceutical companies discussed updates to their investigational P2X3 antagonists, a ...

Trevi Therapeutics (TRVI) is initiated with a "Buy" rating, driven by its lead asset Haduvio’s advancement toward phase 3 testing for chronic cough in IPF. Company's Haduvio demonstrated statistically ...

Credit: Getty Images. Twice daily gefapixant 45 mg was associated with a clinically meaningful reduction in cough frequency in patients with chronic cough. Twice daily gefapixant 45mg was associated ...